Robust TMTT Growth to Drive Edwards Lifesciences' Q2 Earnings
In the last reported quarter, the company's adjusted earnings per share of 64 cents beat the Zacks Consensus Estimate by 6.67%. Its earnings beat estimates in two of the trailing four quarters and matched on the other two occasions, the average surprise being 3.49%.
Q2 Estimates
The Zacks Consensus Estimate for revenues is pegged at $1.49 billion, suggesting an 8.9% decline from the year-ago reported figure.
The Zacks Consensus Estimate for net earnings of 62 cents per share indicates an 11.4% decline from the year-ago reported figure.
Estimate Revision Trend Ahead of Edwards' Q2 Earnings
Estimates for earnings have remained unchanged at 62 cents per share in the past 60 days.
Here's a brief overview of the company's progress ahead of this announcement.
Factors at Play
In the second quarter of 2025, the Transcatheter Aortic Valve Replacement ('TAVR') arm is likely to have delivered a strong performance in the United States, thanks to its market-leading SAPIEN 3 Ultra RESILIA platform. The continued expansion of SAPIEN3 Ultra RESILIA in Europe is expected to have supported the international performance. The platform has demonstrated remarkable patient outcomes, and the momentum is expected to have continued with more centers adopting it. Although we expect the company to have endured a weak procedure growth environment and competitive pressure in Japan, it remained dedicated to addressing significant undertreatment of aortic stenosis among the country's substantial elderly population.
On its previous earnings call, Edwards stated that it experienced a few instances of regional variability despite holding a strong competitive position and stable global pricing. The trend is likely to have continued in the second quarter, restricting the segment's full potential. Our model assumes TAVR sales to be $1.09 billion, implying a 5.2% year-over-year increase.
In the Transcatheter Mitral and Tricuspid Therapies ('TMTT') segment, strength in the portfolio of repair and replacement technologies for both Mitral and Tricuspid valves is likely to have supported Edwards' performance in second-quarter 2025. The PASCAL repair system is expected to have gained traction in the United States, Europe and globally, thanks to its differentiated features, leading to increased adoption of the technology at both existing and new centers.
Additionally, the commercial launch of the EVOQUE tricuspid replacement system might have continued to progress in the United States and Europe. As of March, it gained Medicare coverage under the finalized NCD for transcatheter tricuspid valve replacement, expanding access.
Edwards Lifesciences Corporation Price and EPS Surprise
Edwards Lifesciences Corporation price-eps-surprise | Edwards Lifesciences Corporation Quote
Edwards has raised its 2025 sales guidance for this segment to $530-$550 million (earlier $500 million), and we expect the company to have progressed meaningfully in the to-be-reported quarter. Our model estimates the TMTT business to report revenues of $130.4 million, implying a 57.1% improvement from the year-ago period's level.
Lastly, Edwards' Surgical Structural Heart might have delivered a strong performance in the to-be-reported quarter, driven by global adoption of its premium RESILIA portfolio, including MITRIS, INSPIRIS and KONECT. The company likely saw positive procedural growth globally for the many patients best treated surgically, including complex and concomitant procedures. Furthermore, MITRIS' launch in China with positive surgeon feedback might have contributed to the second-quarter top line.
Our model estimates the segment's revenues to be $263.1 million, suggesting a modest 6.2% rise from the year-ago quarter's reported figure.
Earnings Whispers for Edwards
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below:
Earnings ESP: Edwards has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.
Top MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle:
CVS Health CVS has an Earnings ESP of +2.06% and a Zacks Rank #1 at present. The company is slated to release second-quarter 2025 results on July 31. You can see the complete list of today's Zacks #1 Rank stocks here.
CVS' earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.08%. The Zacks Consensus Estimate for second-quarter EPS implies a year-over-year decline of 19.7%.
Cencora COR has an Earnings ESP of +1.49% and a Zacks Rank #2 at present. The company is slated to release third-quarter fiscal 2025 results on Aug. 6.
The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.00%. The Zacks Consensus Estimate for fiscal third-quarter EPS implies a year-over-year increase of 13.2%.
Cardinal Health CAH has an Earnings ESP of +0.68% and a Zacks Rank #2 at present. The company is expected to release fiscal fourth-quarter 2025 results on Aug. 12.
CAH's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.30%. The Zacks Consensus Estimate for fiscal fourth-quarter EPS suggests a year-over-year improvement of 1.3%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cardinal Health, Inc. (CAH): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
CVS Health Corporation (CVS): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
14 minutes ago
- National Post
Trump's tariff threats against Canada face legal hurdles ahead of August deadline
Donald Trump's plan to realign global trade faces its latest legal barrier this week in a federal appeals court — and Canada is bracing for the U.S. president to follow through on his threat to impose higher tariffs. Article content While Trump set an Aug. 1 deadline for countries to make trade deals with the United States, the president's ultimatum has so far resulted in only a handful of frameworks for trade agreements. Article content Article content Article content Deals have been announced for Japan, Vietnam, Indonesia, the Philippines and the United Kingdom — but Trump indicated last week that an agreement with Canada is far from complete. Article content Trump sent a letter to Prime Minister Mark Carney threatening to impose 35 per cent tariffs if Canada doesn't make a trade deal by the deadline. The White House has said those duties would not apply to goods compliant with the Canada-U.S.-Mexico Agreement on trade. Article content Article content Countries around the world will also be watching as Trump's use of a national security statute to hit nations with tariffs faces scrutiny in the United States Court of Appeals for the Federal Circuit. Article content The U.S. Court of International Trade ruled in May that Trump does not have the authority to wield tariffs on nearly every country through the use of the International Economic Emergency Powers Act of 1977. Article content The act, usually referred to by the acronym IEEPA, gives the U.S. president authority to control economic transactions after declaring an emergency. No previous president had ever used it for tariffs and the U.S. Constitution gives power over taxes and tariffs to Congress. Article content Article content The Trump administration quickly appealed the lower court's ruling on the so-called 'Liberation Day' and fentanyl-related tariffs and arguments are set to be heard in the appeal court on Thursday. Article content George Mason University law professor Ilya Somin called Trump's tariff actions a 'massive power grab.' Somin, along with the Liberty Justice Center, is representing the American small businesses.
CTV News
an hour ago
- CTV News
U.S. says tariff deadline of Aug 1 is firm, no extensions
U.S. President Donald Trump listens to members of the media after he arrived at Prestwick Airport in Ayrshire, Scotland, Friday, July 25, 2025.(AP Photo/Jacquelyn Martin) WASHINGTON — The U.S. deadline of August 1 for imposing tariffs on its trading partners is firm and there will be no extensions, U.S. Commerce Secretary Howard Lutnick said Sunday. 'So no extensions, no more grace periods. August 1, the tariffs are set. They'll go into place. Customs will start collecting the money, and off we go,' Lutnick told 'Fox News Sunday.' After the levies kick in, U.S. President Donald Trump -- who was negotiating Sunday in Scotland with European Union officials -- is still willing to keep talking, Lutnick said. Of the Europeans, Lutnick said, 'You know they're hoping they make a deal, and it's up to President Trump, who's the leader of this negotiating table. We set the table.' So far five countries have struck deals with the Trump administration ahead of the Friday deadline as it tries to overhaul the global system of largely free trade by slapping tariffs on countries that the United States deems as engaging in unfair practices. These five are Britain, Vietnam, Indonesia the Philippines, and Japan. The levies they accepted are often higher than the new base rate of 10 percent that the United States has applied to most countries since April. But they are far below the levels the Trump administration threatened to impose if no deal were reached. AFP
Globe and Mail
an hour ago
- Globe and Mail
Codex Labs to Exhibit at The Society for Pediatric Dermatology's 50th Annual Meeting
Seattle, Wash. - July 22nd, 2025 - Codex Labs, a biotech skincare company focused on microbiome-friendly solutions, is honored to participate in The Society for Pediatric Dermatology's (SPD) 50th Annual Meeting. Taking place from July 23rd to 26th at The Westin Seattle, the event will celebrate five decades of advancing pediatric dermatology through education, research, and collaboration. "Codex Labs is delighted to be attending The Society for Pediatric Dermatology's 50th Annual Meeting and presenting a novel plant-based biotech eczema lotion and cleanser for children as young as 3 weeks old,' says founder and CEO Dr. Barbara Paldus. 'We believe that these new topicals, when combined and targeted with pre- and probiotics, will usher in a future of highly effective, steroid-free alternatives for the management of pediatric atopic dermatitis." The SPD comprises over 1,800 members worldwide, including pediatricians, dermatologists, pediatric dermatologists, and other healthcare professionals. At this year's milestone 50th SPD Annual Meeting, Codex Labs will be one of many organizations gathering to support the advancement of pediatric dermatology. The SPD's 50th Annual Meeting will take place over four days and feature networking opportunities, support group discussions, lecture sessions, companies and exhibitors showcasing their products, and organizations dedicated to pediatric dermatology research and advancement. Some key topics highlighted at this year's meeting include infections, medications and therapies, psoriasis and inflammatory skin conditions, tumors and neoplasms, vascular lesions, and more. Codex Labs will be attending this year's 50th Annual Meeting and sponsoring the Early Career Networking Reception on Wednesday, July 23rd at 6:00 pm. This event is for medical doctors completing a fellowship or those out of training for five years or less, where they can share experiences and connect with other young dermatologists. Dr. Jessica Maloh, Naturopathic Doctor and Head of Naturopathic Medicine at Codex Labs, will be attending the event and presenting a research poster that highlights the use of oral probiotics as adjunctive interventions for acne. 'Acne is one of the most common skin conditions affecting adolescents, often impacting not only the skin, but also self-esteem and quality of life,' says Dr. Maloh. 'At the SPD, I'm excited to share a summary of the research on the adjunctive use of oral probiotics in acne management- an intervention that may complement conventional dermatologic treatments like antibiotics and oral isotretinoin. Integrative strategies like this have been found to enhance acne treatment efficacy while also supporting the gut microbiome.' Codex Labs is honored to participate in the 50th Annual Meeting and looks forward to showcasing its products and findings. Dr. Maloh invites guests to the Networking Reception and to visit her team's presentation to learn more about their skincare breakthroughs and the latest in integrative dermatology research. Event Details: Location: The Westin Seattle, located at 1900 5th Ave, Seattle, WA 98101. For more information about Codex Labs and its products, please visit If you are interested in learning more about Codex Labs' participation in The SPD's 50th Annual Meeting, please contact About Codex Labs: Based in Silicon Valley and led by scientist Dr. Barb Paldus, Codex Labs is committed to creating highly effective, clinically proven, microbiome-supporting skin-gut-brain-biome solutions that contain potent, biotech-derived plant-based actives. Codex Labs' products focus on restoring/protecting the skin barrier, managing inflammation, and addressing skin conditions associated with aging, acne, eczema, and psoriasis. The brand has been heralded by integrative dermatologists and naturopathic doctors for creating the next generation of effective, vegan, cruelty-free, and sustainable plant-based solutions.
